HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TRANSTHERA-B

10.070

0.000

Volume:- -

Turnover:- -

Market Cap:4.10B

PE:-11.32

High:10.070

Open:10.070

Low:10.070

Close:10.070

52wk High:246.000

52wk Low:9.010

Shares:407.00M

HK Float Shares:312.00M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.890

ROE:-36.78%

ROA:-20.32%

PB:3.99

PE(LYR):-11.32

PS:98.72

Loading ...

Overview Company News Filings

TransThera Sciences completes HK$290 million H-share placement at HK$57.03 each

TRANSTHERA-B (02617) Presents Lineage Plasticity as Resistance Mechanism in HR+ Breast Cancer Endocrine Therapy and Preclinical Data for Tiengotinib at 2026 AACR

TransThera Highlights FGFR-JAK–Mediated Resistance in HR+ Breast Cancer and Showcases Tinengotinib Preclinical Efficacy at AACR 2026

Bulletin Express

TransThera Sciences presents tinengotinib preclinical data at AACR annual meeting

TransThera Sciences Doses First Patient in Cholangiocarcinoma Drug Trial

MT Newswires Live

TRANSTHERA-B (02617): First Patient Dosed in Confirmatory Phase III Trial of Tinengotinib Monotherapy for Advanced Cholangiocarcinoma

TransThera doses first patient in China Phase III tinengotinib trial for advanced cholangiocarcinoma

TRANSTHERA-B Announces Private Placement of 5.085 Million Shares at 18% Discount

TransThera Sciences announces HK$290.00 million H-share placement; 5.09 million new shares priced at 18% discount

Bulletin Express

TransThera Sciences to place 5,085,000 new H shares at HK$57.03 each

Transthera Sciences (Nanjing) Inc - Placing of 5.1 Mln Shares at HK$57.03 per Share

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/02617/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":10.07,"timestamp":1791508170229,"preClose":10.07,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":312000000,"shares":407000000,"eps":-0.8898862896201023,"marketStatus":"Pre-opening","change":0,"latestTime":"10-09 09:21:47","open":10.07,"high":10.07,"low":10.07,"amount":0,"amplitude":0,"askPrice":10.19,"askSize":1000,"bidPrice":9.99,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-0.7875189228354614,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791509400000},"marketStatusCode":1,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":10.07,"openAndCloseTimeList":[[1791509400000,1791518400000],[1791522000000,1791532800000]],"volumeRatio":0,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":312000000,"roa":"-20.32%","roe":"-36.78%","lyrEps":-0.889886,"shares":407000000,"dividePrice":0,"high":10.07,"amplitude":0,"preClose":10.07,"low":10.07,"week52Low":9.01,"pbRate":"3.99","psRate":"98.72","week52High":246,"institutionHeld":0,"latestPrice":10.07,"committee":0.2,"eps":-0.8898862896201023,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.7875189228354614,"open":10.07,"prevYearClose":114.9,"fiveDayClose":10.72,"twentyDayClose":9.46,"sixtyDayClose":10.95},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"market":"HK","date":"2026-03-31","symbol":"02617","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774886400000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2026-10-08","current":-12.443714,"percent":0.85625,"low":-380.446233,"twenty":-180.799135,"median":-68.232426,"eighty":-13.78901,"high":-10.87103,"avg":-104.295856,"sd":96.208876,"marketCap":4101195134},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642},{"date":"2025-09-12","current":-176.221101,"twenty":-67.557018,"median":-51.642061,"eighty":-40.181616,"marketCap":76402794352},{"date":"2025-09-19","current":-137.321051,"twenty":-71.134174,"median":-54.042597,"eighty":-40.68225,"marketCap":59494955186},{"date":"2025-09-26","current":-219.814439,"twenty":-72.736767,"median":-55.62397,"eighty":-41.23574,"marketCap":56835741045},{"date":"2025-10-03","current":-208.418403,"twenty":-113.88308,"median":-57.213624,"eighty":-41.375772,"marketCap":54017767851},{"date":"2025-10-10","current":-183.264838,"twenty":-172.633767,"median":-57.790453,"eighty":-41.583173,"marketCap":47429267143},{"date":"2025-10-17","current":-311.562728,"twenty":-178.967921,"median":-58.015216,"eighty":-41.927636,"marketCap":80570219499},{"date":"2025-10-24","current":-293.038662,"twenty":-206.454369,"median":-63.574223,"eighty":-42.029097,"marketCap":75807447903},{"date":"2025-10-31","current":-281.572204,"twenty":-212.338922,"median":-65.741367,"eighty":-42.067733,"marketCap":72949784945},{"date":"2025-11-07","current":-338.772318,"twenty":-240.199465,"median":-68.232426,"eighty":-42.195906,"marketCap":87714376893},{"date":"2025-11-14","current":-312.135011,"twenty":-262.893893,"median":-70.289151,"eighty":-42.482614,"marketCap":81046496658},{"date":"2025-11-21","current":-312.892206,"twenty":-281.392507,"median":-71.392356,"eighty":-43.133487,"marketCap":81205255711},{"date":"2025-11-28","current":-305.66478,"twenty":-292.6573,"median":-72.756691,"eighty":-44.126885,"marketCap":79617665179},{"date":"2025-12-05","current":-292.058382,"twenty":-294.387608,"median":-99.507708,"eighty":-45.187328,"marketCap":76204345536},{"date":"2025-12-12","current":-243.995471,"twenty":-293.167092,"median":-152.573856,"eighty":-47.193393,"marketCap":63781449623},{"date":"2025-12-19","current":-248.269013,"twenty":-292.997062,"median":-174.177612,"eighty":-49.176233,"marketCap":65051522048},{"date":"2025-12-24","current":-196.609225,"twenty":-292.87226,"median":-176.029803,"eighty":-49.50215,"marketCap":51676071816},{"date":"2026-01-02","current":-170.268162,"twenty":-292.367293,"median":-176.029803,"eighty":-50.024601,"marketCap":44928812055},{"date":"2026-01-09","current":-172.395935,"twenty":-291.502465,"median":-173.687618,"eighty":-50.606284,"marketCap":45603538031},{"date":"2026-01-16","current":-142.824051,"twenty":-290.689477,"median":-172.622298,"eighty":-50.90198,"marketCap":37903723951},{"date":"2026-01-23","current":-125.658859,"twenty":-289.035292,"median":-170.268162,"eighty":-51.777834,"marketCap":33316302355},{"date":"2026-01-30","current":-123.813683,"twenty":-286.862177,"median":-169.566856,"eighty":-52.840115,"marketCap":32977154367},{"date":"2026-02-06","current":-105.494623,"twenty":-283.350344,"median":-167.82666,"eighty":-53.700055,"marketCap":28169232889},{"date":"2026-02-13","current":-102.143547,"twenty":-281.033113,"median":-142.637109,"eighty":-54.549461,"marketCap":27431087268},{"date":"2026-02-20","current":-99.091969,"twenty":-280.673719,"median":-140.820404,"eighty":-54.88737,"marketCap":26573242357},{"date":"2026-02-27","current":-101.401985,"twenty":-277.873293,"median":-135.446139,"eighty":-55.077905,"marketCap":27490936913},{"date":"2026-03-06","current":-136.499284,"twenty":-268.489172,"median":-127.818396,"eighty":-56.170035,"marketCap":36707782236},{"date":"2026-03-13","current":-113.20329,"twenty":-265.946326,"median":-125.658859,"eighty":-56.966285,"marketCap":30583168569},{"date":"2026-03-20","current":-101.699451,"twenty":-264.885138,"median":-122.419285,"eighty":-57.460964,"marketCap":27371237623},{"date":"2026-03-27","current":-103.891016,"twenty":-259.5894,"median":-118.720319,"eighty":-57.713018,"marketCap":27889934546},{"date":"2026-04-02","current":-103.689961,"twenty":-256.279611,"median":-116.735022,"eighty":-57.836913,"marketCap":27969734073},{"date":"2026-04-10","current":-80.663784,"twenty":-255.242863,"median":-113.754326,"eighty":-57.879207,"marketCap":27371237623},{"date":"2026-04-17","current":-81.335146,"twenty":-254.749157,"median":-113.20329,"eighty":-57.943799,"marketCap":27610636203},{"date":"2026-04-24","current":-69.75013,"twenty":-253.791099,"median":-110.250158,"eighty":-58.025793,"marketCap":23679242293},{"date":"2026-04-30","current":-61.379887,"twenty":-252.626844,"median":-107.193308,"eighty":-58.709304,"marketCap":20850663862},{"date":"2026-05-08","current":-65.459145,"twenty":-251.564027,"median":-106.48355,"eighty":-58.020504,"marketCap":22305361341},{"date":"2026-05-15","current":-57.457667,"twenty":-249.188687,"median":-106.083059,"eighty":-57.919993,"marketCap":19630334311},{"date":"2026-05-22","current":-50.784784,"twenty":-247.674355,"median":-104.198267,"eighty":-57.649604,"marketCap":17310899997},{"date":"2026-05-29","current":-41.763424,"twenty":-245.295721,"median":-103.852131,"eighty":-57.457667,"marketCap":14285310527},{"date":"2026-06-05","current":-37.606441,"twenty":-243.995471,"median":-103.234551,"eighty":-55.321243,"marketCap":12882070430},{"date":"2026-06-12","current":-38.299212,"twenty":-239.592317,"median":-102.28828,"eighty":-53.347698,"marketCap":13110504864},{"date":"2026-06-18","current":-33.64261,"twenty":-235.649979,"median":-102.143547,"eighty":-51.161877,"marketCap":11544097313},{"date":"2026-06-26","current":-10.87103,"twenty":-223.802745,"median":-101.125662,"eighty":-50.162538,"marketCap":3712059560},{"date":"2026-07-03","current":-14.085963,"twenty":-220.323597,"median":-100.505297,"eighty":-47.51031,"marketCap":4813439869},{"date":"2026-07-10","current":-12.489761,"twenty":-217.694001,"median":-99.314488,"eighty":-43.652943,"marketCap":4262749714},{"date":"2026-07-17","current":-11.456979,"twenty":-215.893769,"median":-98.774546,"eighty":-42.55123,"marketCap":3924177249},{"date":"2026-07-24","current":-12.133097,"twenty":-213.808047,"median":-93.131819,"eighty":-41.957553,"marketCap":4156690870},{"date":"2026-07-31","current":-11.824868,"twenty":-212.088453,"median":-87.290837,"eighty":-41.541423,"marketCap":4058790398},{"date":"2026-08-07","current":-13.332054,"twenty":-210.416628,"median":-83.155604,"eighty":-40.356892,"marketCap":4585005434},{"date":"2026-08-14","current":-12.237188,"twenty":-208.788963,"median":-82.408413,"eighty":-39.630155,"marketCap":4213799478},{"date":"2026-08-21","current":-12.186563,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"marketCap":4205641106},{"date":"2026-08-28","current":-13.544101,"twenty":-206.454369,"median":-79.928564,"eighty":-37.623415,"marketCap":4242353783},{"date":"2026-09-04","current":-13.213217,"twenty":-200.748681,"median":-72.756691,"eighty":-35.040401,"marketCap":4140374124},{"date":"2026-09-11","current":-12.187879,"twenty":-194.548173,"median":-71.729981,"eighty":-33.11771,"marketCap":3824237184},{"date":"2026-09-18","current":-13.02239,"twenty":-188.179892,"median":-71.163303,"eighty":-16.078674,"marketCap":4091423888},{"date":"2026-09-25","current":-13.026466,"twenty":-182.801065,"median":-69.75013,"eighty":-14.040359,"marketCap":4084904388},{"date":"2026-10-02","current":-13.90794,"twenty":-181.844152,"median":-68.633717,"eighty":-13.915844,"marketCap":4365919745},{"date":"2026-10-08","current":-13.04836,"twenty":-180.799135,"median":-68.232426,"eighty":-13.78901,"marketCap":4101195134}],"updateTime":1791508019067},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2629333070","title":"TransThera Sciences completes HK$290 million H-share placement at HK$57.03 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2629333070","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629333070?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:04","pubTimestamp":1776769486,"startTime":"0","endTime":"0","summary":"TransThera Sciences completed private placement of 5,085,000 new H shares at HK$ 57.03 each on April 21, 2026.Gross proceeds totaled about HK$ 290 million; net proceeds were about HK$ 282.2 million.Funds earmarked mainly for R&D and clinical development of Tinengotinib, with additional allocation toward manufacturing and commercialization in China.Total issued shares rose to 404,082,633 from 398,997,633 following issue of placing shares.Placees bought about 1.3% of enlarged share capital; none became substantial shareholder.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Excha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL48jwCt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121493501","title":"TRANSTHERA-B (02617) Presents Lineage Plasticity as Resistance Mechanism in HR+ Breast Cancer Endocrine Therapy and Preclinical Data for Tiengotinib at 2026 AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=1121493501","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121493501?lang=en_us&edition=fundamental","pubTime":"2026-04-21 08:10","pubTimestamp":1776730218,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that the company presented a poster at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The poster disclosed lineage plasticity as a driver...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK4203","BK1161","HR","BK4225"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184291572","title":"TransThera Highlights FGFR-JAK–Mediated Resistance in HR+ Breast Cancer and Showcases Tinengotinib Preclinical Efficacy at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1184291572","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184291572?lang=en_us&edition=fundamental","pubTime":"2026-04-21 08:02","pubTimestamp":1776729777,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (TransThera) released new translational and preclinical findings at the 2026 American Association for Cancer Research (AACR) Annual Meeting, identifying lineage...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629041772","title":"TransThera Sciences presents tinengotinib preclinical data at AACR annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629041772","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629041772?lang=en_us&edition=fundamental","pubTime":"2026-04-21 08:00","pubTimestamp":1776729643,"startTime":"0","endTime":"0","summary":"TransThera Sciences will present a poster at AACR Annual Meeting on April 20, 2026, 9:00 AM–12:00 PM PDT.Presentation will cover endocrine therapy resistance in HR+ breast cancer, citing convergent FGFR-JAK signaling as a driver of lineage reprogramming.Poster will also show preclinical data indicating tinengotinib restored luminal identity, resensitizing resistant models to endocrine therapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL3vdWMH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628278208","title":"TransThera Sciences Doses First Patient in Cholangiocarcinoma Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2628278208","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628278208?lang=en_us&edition=fundamental","pubTime":"2026-04-17 19:10","pubTimestamp":1776424232,"startTime":"0","endTime":"0","summary":"TransThera Sciences   dosed the first patient in a confirmatory phase III clinical trial of Tinengotinib, according to a Friday Hong Kong bourse filing.The drug is being tested as a monotherapy for the treatment of patients with advanced cholangiocarcinoma, the clinical-stage biopharmaceutical firm said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176775881","title":"TRANSTHERA-B (02617): First Patient Dosed in Confirmatory Phase III Trial of Tinengotinib Monotherapy for Advanced Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1176775881","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176775881?lang=en_us&edition=fundamental","pubTime":"2026-04-17 18:44","pubTimestamp":1776422683,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that the first patient has been dosed in a confirmatory Phase III clinical study evaluating its core product, Tinengotinib (TT-00420), as a monotherapy for patients...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","02617","BK4134","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628270114","title":"TransThera doses first patient in China Phase III tinengotinib trial for advanced cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2628270114","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628270114?lang=en_us&edition=fundamental","pubTime":"2026-04-17 18:40","pubTimestamp":1776422454,"startTime":"0","endTime":"0","summary":"TransThera dosed first patient in China confirmatory Phase III trial of tinengotinib monotherapy for advanced intrahepatic cholangiocarcinoma with FGFR2 alterations.Study will compare tinengotinib versus chemotherapy in patients whose disease relapsed or progressed following first-line systemic therapy.No clinical results were presented; efficacy and safety readout will be generated in future as trial progresses.Program supports marketing push in China, with tinengotinib already at NDA review stage following completion of pivotal Phase II study.Company positioned drug as potential option for patients previously treated with FGFR inhibitors, targeting unmet need tied to treatment resistance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL57VbVH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121459065","title":"TRANSTHERA-B Announces Private Placement of 5.085 Million Shares at 18% Discount","url":"https://stock-news.laohu8.com/highlight/detail?id=1121459065","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121459065?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:06","pubTimestamp":1776207983,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) has entered into a placement agreement with a placement agent. The agreement, dated April 14, 2026, stipulates that the agent will use its best efforts to place 5.085 million...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178263361","title":"TransThera Sciences announces HK$290.00 million H-share placement; 5.09 million new shares priced at 18% discount","url":"https://stock-news.laohu8.com/highlight/detail?id=1178263361","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178263361?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:43","pubTimestamp":1776206599,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (abbreviated “TransThera Sciences”) on 14 April 2026 signed a conditional placing agreement with Macquarie Capital Limited to issue 5.09 million new H shares at...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627291427","title":"TransThera Sciences to place 5,085,000 new H shares at HK$57.03 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2627291427","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627291427?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:32","pubTimestamp":1776205929,"startTime":"0","endTime":"0","summary":"TransThera Sciences entered a placing agreement to sell 5,085,000 new H shares at HK$ 57.03 each.Deal size implies gross proceeds of about HK$ 290 million.Pricing represents an 18% discount to April 14 close of HK$ 69.55.Net proceeds expected at about HK$ 282.2 million.Funds earmarked mainly for R&D and Tinengotinib manufacturing and commercialization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 14, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL3kD9vl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627542725","title":"Transthera Sciences (Nanjing) Inc -  Placing of 5.1 Mln Shares at HK$57.03 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2627542725","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627542725?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:31","pubTimestamp":1776205891,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40X16U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":7,"totalSize":131,"code":"91000000","status":"200"}]}}